The TTS transtracheal catheter is designed to deliver oxygen directly to where it is most needed, the lungs. Transtracheal Systems, Inc. (TTS) provides all the necessary products and documentation to fully support a patient throughout the entire TTO program. Transtracheal oxygen therapy (TTOT) is compatible with all oxygen delivery methods, including compressed gas, stationary liquid, portable liquid, stationary and portable oxygen concentrators (POCs). For more detailed information, please contact Technical Services at email@example.com.
FEDERAL LAW (USA) RESTRICTS THIS PRODUCT TO SALE BY OR ON THE ORDER OF A PHYSICIAN
Transtracheal oxygen is indicated for patients with chronic hypoxemia which persists in spite of optimal medical therapy. Arterial blood gases obtained while breathing room air should show a PaO2< 55 mm Hg. Transtracheal oxygen is also indicated for patients with a PaO2 of 56-59 mm Hg if they also have: 1) dependent edema suggesting congestive heart failure, 2) "P" pulmonale on EKG (P wave greater than 3mm in standard leads II, III or AVF), or 3) erythrocythemia with a hematocrit of >55%.
Specific indications for Transtracheal oxygen therapy include:
- need for improved mobility
- suboptimal compliance related to nasal cannula
- complications of nasal cannula
- cor pulmonale or erythrocythemia on nasal oxygen
- refractory hypoxemia
- patient preference.
Transtracheal oxygen requires a fair degree of patient participation and should not be used in patients who are unable to understand and/or carry out the patient instructions. Because of the risk of pneumothorax, the procedure should not be performed if a pre-procedure chest x-ray shows pleural herniation over the selected puncture site. Transtracheal oxygen also should not be used if subglottic stenosis, bilateral vocal cord paralysis or any other cause of upper airway obstruction is present.
(Click here to see Product Photos)